Correlation Engine 2.0
Clear Search sequence regions

  • cancer (3)
  • emesis (1)
  • humans (1)
  • nausea (9)
  • organ risk (1)
  • patients (9)
  • research (1)
  • switzerland (1)
  • Sizes of these terms reflect their relevance to your search.

    Chemotherapy-induced nausea and vomiting (CINV) are still two of the most feared side effects of cancer therapy. Although major progress in the prophylaxis of CINV has been made during the past 40 years, nausea in particular remains a significant problem. Older patients have a lower risk of CINV than younger patients, but are at a higher risk of severe consequences of dehydration and electrolyte disturbances following emesis. Age-related organ deficiencies, comorbidities, polypharmacy, risk of drug-drug interactions, and lack of compliance all need to be addressed in the older patient with cancer at risk of CINV. Guidelines provide evidence-based recommendations for the prophylaxis of CINV, but none of these guidelines offer specific recommendations for older patients with cancer. This means that the recommendations may lead to overtreatment in some older patients. This review describes the development of antiemetic prophylaxis of CINV focusing on older patients, summarizes recommendations from antiemetic guidelines, describes deficiencies in our knowledge of older patients, summarizes necessary precautions, and suggests some future perspectives for antiemetic research in older patients. © 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.


    Jørn Herrstedt, Sanne Lindberg, Peter Clausager Petersen. Prevention of Chemotherapy-Induced Nausea and Vomiting in the Older Patient: Optimizing Outcomes. Drugs & aging. 2022 Jan;39(1):1-21

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 34882284

    View Full Text